This review discusses current data on CNS lesions in infections with the new coronavirus that causes COVID-19. The pathogenetic mechanisms leading to infection of the brain and spinal cord are presented. Published studies and meta-analyses published by autumn 2020 are assessed. The authors present results from their own clinical observations of various types of CNS infection in COVID-19 virus disease. Particular attention is paid to certain common forms of CNS lesion such as encephalitis, cerebrovascular pathology, and headache. A form of acute hemorrhagic necrotic encephalopathy is identified, which is a quite rare but fatal pathology comorbid with COVID-19. A description of our own clinical observation of acute necrotic encephalopathy is presented. The importance of further studies of the effects of the coronavirus on the CNS and possible approaches to treatment and rehabilitation of this category of patients is emphasized.
Article PDF
Similar content being viewed by others
References
H. R. Niazkar, B. Zibaee, A. Nasimi, and N. Bahri, “The neurological manifestations of COVID-19: a review article,” Neurol. Sci., 41, No. 7, 1667–1671 (2020), https://doi.org/10.1007/s10072-020-04486-3.
I. Ahmad and F. A. Rathore, “Neurological manifestations and complications of COVID-19: a literature review,” J. Clin. Neurosci., 77, 8–12 (2020), https://doi.org/10.1016/j.jocn.2020.05.017.
World Health Organization, Coronavirus Disease (COVID-19) Situation Report – 160, Data as Received by WHO from National Authorities by 10:00 CEST, June 28, 2020, https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200628-covid-19-sitrep-160.pdf?sfvrsn=2fe1c658_2, acc. Aug. 27, 2020.
R. Bridwell, B. Long, and M. Gottlieb, “Neurologic complications of COVID-19,” Am. J. Emerg. Med., 38, No. 7, 1549.e3–1549.e7 (2020), https://doi.org/10.1016/j.ajem.2020.05.024.
H. Fan, X. Tang, Y. Song, et al., “Influence of COVID-19 on cerebrovascular disease and its possible mechanism,” Neuropsychiatr. Dis. Treat., 16, 1359–1367 (2020), https://doi.org/10.2147/NDT.S251173.
G. Tsivgoulis, L. Palaiodimou, A. H. Katsanos, et al., “Neurological manifestations and implications of COVID-19 pandemic,” Ther. Adv. Neurol. Disord., 13, 1756286420932036 (2020), https://doi.org/10.1177/1756286420932036.
D. Wang, B. Hu, C. Hu, et al., “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China,” JAMA, 323, No. 11, 1061–1069 (2020), https://doi.org/10.1001/jama.2020.1585.
J. Wang, N. Hajizadeh, E. E. Moore, et al., “Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS), a case series,” J. Thromb. Haemost., 18, No. 7, 1752–1755 (2020), https://doi.org/10.1111/jth.14828.
N. Tang, H. Bai, X. Chen, et al., “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy,” J. Thromb. Haemost., 18, No. 5, 1094–1099 (2020), https://doi.org/10.1111/jth.14817.
Y. C. Li, W. Z. Bai, and T. Hashikawa, “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients,” J. Med. Virol., 92, No. 6, 552–555 (2020), https://doi.org/10.1002/jmv.25728.
H. Cheng, Y. Wang, and G. Q. Wang, “Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19,” J. Med. Virol., 92, No. 7, 726–730 (2020), https://doi.org/10.1002/jmv.2578.
L. Steardo, L. Steardo, Jr., R. Zorec, and A. Verkhratsky, “Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19,” Acta Physiol., 229, No. 3, e13473 (2020), https://doi.org/10.1111/apha.13473.
H. C. Yashavantha Rao and C. Jayabaskaran, “The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients,” J. Med. Virol., 92, No. 7, 786–790 (2020), https://doi.org/10.1002/jmv.25918.
M. Sheraton, N. Deo, R. Kashyap, and S. Surani, “A review of neurological complications of COVID-19,” Cureus, 12, No. 5, e8192 (2020), https://doi.org/10.7759/cureus.8192.
H. Tu, S. Tu, S. Gao, et al., “The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event,” J. Infect., 81, No. 1, 1–9 (2020), https://doi.org/10.1016/j.jinf.2020.04.011.
K. Tveito, “Cytokine storms in COVID-19 cases,” Tidsskr. Nor. Laegeforen, 23, 140 (2020), https://doi.org/10.4045/tidsskr.20.0239.
A. Filatov, P. Sharma, and F. Hindi, “Neurological complications of coronavirus disease COVID-19, encephalopathy,” Cureus, 12, No. 3, e7352 (2020), https://doi.org/10.7759/cureus.7352.
A. J. Rodriguez-Morales, J. A. Cardona-Ospina, E. Gutiérrez-Ocampo, et al., “Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis,” Travel Med. Infect. Dis., 34, 101623 (2020), https://doi.org/10.1016/j.tmaid.2020.101623.
L. Mao, H. Jin, M. Wang, et al., “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China,” JAMA Neurol., 77, No. 6, 1–9 (2020), https://doi.org/10.1001/jamaneurol.2020.1127.
T. Scullen, J. Keen, M. Mathkour, et al., “Coronavirus 2019 (COVID-19)-Associated encephalopathies and cerebrovascular disease: The New Orleans experience,” World Neurosurg, 141, e437–e446 (2020), https://doi.org/10.1016/j.wneu.2020.05.192.
A. O. Correia, P. W. G. Feitosa, J. L. D. S. Moreira, et al., “Neurological manifestations of COVID-19 and other coronaviruses: a systematic review,” Neurol. Psychiatry Brain Res., 37, 27–32 (2020), https://doi.org/10.1016/j.npbr.2020.05.008.
A. Azhideh, “COVID-19 neurological manifestations,” Int. Clin. Neurosci. J., 7, No. 2, 54 (2020), https://doi.org/10.34172/icnj.2020.01.
S. T. Reddy, T. Garg, C. Shah, et al., “Cerebrovascular disease in patients with COVID-19: a review of the literature and case series,” Case Rep. Neurol., 12, No. 2, 199–209 (2020), https://doi.org/10.1159/000508958.
Y. Wu, X. Xu, Z. Chen, et al., “Nervous system involvement after infection with COVID-19 and other coronaviruses,” Brain Behav. Immun., 87, 18–22 (2020), https://doi.org/10.1016/j.bbi.2020.03.031.
N. Poyiadji, G. Shahin, D. Noujaim, et al., “COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features,” Radiology, 296, No. 2, 119–120 (2020), https://doi.org/10.1148/radiol.2020201187.
P. Xiang, X. M. Xu, L. L. Gao, et al., “First case of 2019 novel coronavirus disease with encephalitis,” ChinaXiv, T202003.00015 (2020).
T. Moriguchi, N. Harii, J. Goto, et al., “A fi rst case of meningitis/encephalitis associated with SARS-Coronavirus-2,” Int. J. Infect. Dis., 94, 55–58 (2020), https://doi.org/10.1016/j.ijid.2020.03.062.
R. Brüggemann, H. Gietema, B. Jallah, et al., “Arterial and venous thromboembolic disease in a patient with COVID-19: a case report,” Thromb. Res., 191, 153–155 (2020), https://doi.org/10.1016/j.thromres.2020.04.046.
T. Chen, D. Wu, H. Chen, et al., “Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,” BMJ, 368, m1091 (2020), https://doi.org/10.1136/bmj.m1091.
R. Bridwell, B. Long, and M. Gottlieb, “Neurologic complications of COVID-19,” Am. J. Emerg. Med., 38, No. 7, 1549.e3–1549.e7 (2020), https://doi.org/10.1016/j.ajem.2020.05.024.
A. Filatov, P. Sharma, F. Hindi, and P. S. Espinosa, “Neurological complications of coronavirus disease (COVID-19): encephalopathy,” Cureus, 12, No. 3, e7352 (2020), https://doi.org/10.7759/cureus.7352.
M. Benger, O. Williams, J. Siddiqui, and L. Sztriha, “Intracerebral haemorrhage and COVID-19: clinical characteristics from a case series,” Brain Behav. Immun., 88, 940–944 (2020), https://doi.org/10.1016/j.bbi.2020.06.005.
A. Sharifi-Razavi, N. Karimi, and N. Rouhani, “COVID-19 and intracerebral haemorrhage: causative or coincidental,” New Microbes New Infect., 35, 100669 (2020), https://doi.org/10.1016/j.nmni.2020.100669.
J. Sotoca and Y. Rodríguez-Álvarez, “COVID-19-associated acute necrotizing myelitis,” Neurol. Neuroimmunol. Neuroinfl amm., 7, No. 5, e803 (2020), https://doi.org/10.1212/NXI.0000000000000803.
R. AlKetbi, D. AlNuaimi, M. AlMulla, et al., “Acute myelitis as a neurological complication of Covid-19: a case report and MRI findings,” Radiol. Case Rep., 15, No. 9, 1591–1595 (2020), https://doi.org/10.1016/j.radcr.2020.06.001.
M. Munz, S. Wessendorf, G. Koretsis, et al., “Acute transverse myelitis after COVID-19 pneumonia,” J. Neurol., 267, No. 8, 2196–2197 (2020), https://doi.org/10.1007/s00415-020-09934-w.
N. Poyiadji, P. Cormier, P. Y. Patel, et al., “Acute pulmonary embolism and COVID-19,” Radiology, 297, No. 3, 335–338 (2020), https://doi.org/10.1148/radiol.2020201955.
N. Tang, H. Bai, X. Chen, et al., “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy,” J. Thromb. Haemost., 18, No. 5, 1094–1099 (2020), https://doi.org/10.1111/jth.14817.
M. Desforges, A. Le Coupanec, P. Dubeau, et al., “Human coronaviruses and other respiratory Viruses: underestimated opportunistic pathogens of the central nervous system,” Viruses, 12, No. 1, 14 (2019), https://doi.org/10.3390/v12010014.
F. Liu, L. Li, M. Xu, et al., “Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19,” J. Clin. Virol., 127, 104370 (2020), https://doi.org/10.1016/j.jcv.2020.104370.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 1, Iss. 1, pp. 92–97, January, 2021.
Rights and permissions
About this article
Cite this article
Kurushina, O.V., Barulin, A.E. Central Nervous System Lesions in COVID-19. Neurosci Behav Physi 51, 1222–1227 (2021). https://doi.org/10.1007/s11055-021-01183-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-021-01183-2